These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38804784)

  • 21. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review.
    Guven DC; Kavgaci G; Erul E; Syed MP; Magge T; Saeed A; Yalcin S; Sahin IH
    Oncologist; 2024 May; 29(5):e580-e600. PubMed ID: 38309719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of immune checkpoint inhibitor in colorectal cancer].
    Kitano S
    Nihon Rinsho; 2016 Nov; 74(11):1818-1820. PubMed ID: 30550688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
    Zheng Y; Fu Y; Wang PP; Ding ZY
    Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
    Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
    World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer.
    Xiong Y; Wang Y; Tiruthani K
    Nanomedicine; 2019 Oct; 21():102034. PubMed ID: 31207314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
    Kamal Y; Schmit SL; Frost HR; Amos CI
    Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
    Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
    Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for the treatment of colorectal cancer.
    Lumish MA; Cercek A
    J Surg Oncol; 2021 Mar; 123(3):760-774. PubMed ID: 33595891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for colorectal cancer: insight from inherited genetics.
    Tjader NP; Toland AE
    Trends Cancer; 2024 May; 10(5):444-456. PubMed ID: 38360438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.
    El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
    J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
    Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
    Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
    Kishore C; Bhadra P
    Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer.
    Li S; Na R; Li X; Zhang Y; Zheng T
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188758. PubMed ID: 35809762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
    Wang Q; Shen X; Chen G; Du J
    Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The colorectal cancer immune microenvironment and approach to immunotherapies.
    Koi M; Carethers JM
    Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
    Wang D; Zhang H; Xiang T; Wang G
    Front Immunol; 2021; 12():762341. PubMed ID: 34721435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.